EP2124968A4 - Zusammensetzungen und verfahren zur behandlung von muskelschwund - Google Patents
Zusammensetzungen und verfahren zur behandlung von muskelschwundInfo
- Publication number
- EP2124968A4 EP2124968A4 EP06774377.3A EP06774377A EP2124968A4 EP 2124968 A4 EP2124968 A4 EP 2124968A4 EP 06774377 A EP06774377 A EP 06774377A EP 2124968 A4 EP2124968 A4 EP 2124968A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- treatment
- methods
- muscle wasting
- wasting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2006/025657 WO2008005002A1 (en) | 2006-06-30 | 2006-06-30 | Compositions and methods for the treatment of muscle wasting |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2124968A1 EP2124968A1 (de) | 2009-12-02 |
EP2124968A4 true EP2124968A4 (de) | 2013-10-23 |
Family
ID=37102772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06774377.3A Withdrawn EP2124968A4 (de) | 2006-06-30 | 2006-06-30 | Zusammensetzungen und verfahren zur behandlung von muskelschwund |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2124968A4 (de) |
AU (1) | AU2006345724B2 (de) |
CA (1) | CA2558160C (de) |
WO (1) | WO2008005002A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2351976T3 (es) | 2003-04-29 | 2011-02-14 | Avi Biopharma, Inc. | Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células. |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
EP3302489A4 (de) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten |
WO2018118599A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
AU2019206634A1 (en) * | 2018-01-12 | 2020-07-23 | Keros Therapeutics, Inc. | Activin receptor type IIB variants and methods of use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003006478A1 (en) * | 2001-07-10 | 2003-01-23 | Oligos Etc. Inc. | Oligonucleotide-containing pharmacological compositions and their use |
US20030129171A1 (en) * | 1997-07-14 | 2003-07-10 | Luc Grobet | Double-muscling in mammals |
US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
CN1718194A (zh) * | 2005-06-24 | 2006-01-11 | 奥林格斯技术有限公司 | 治疗肌肉萎缩的寡核苷酸药物 |
WO2006086667A2 (en) * | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
-
2006
- 2006-06-30 CA CA2558160A patent/CA2558160C/en not_active Expired - Fee Related
- 2006-06-30 AU AU2006345724A patent/AU2006345724B2/en not_active Ceased
- 2006-06-30 WO PCT/US2006/025657 patent/WO2008005002A1/en active Application Filing
- 2006-06-30 EP EP06774377.3A patent/EP2124968A4/de not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030129171A1 (en) * | 1997-07-14 | 2003-07-10 | Luc Grobet | Double-muscling in mammals |
US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
WO2003006478A1 (en) * | 2001-07-10 | 2003-01-23 | Oligos Etc. Inc. | Oligonucleotide-containing pharmacological compositions and their use |
WO2006086667A2 (en) * | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
CN1718194A (zh) * | 2005-06-24 | 2006-01-11 | 奥林格斯技术有限公司 | 治疗肌肉萎缩的寡核苷酸药物 |
Non-Patent Citations (8)
Title |
---|
ACOSTA J ET AL: "Myostatin gene silenced by RNAi show a zebrafish giant phenotype", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 119, no. 4, 10 October 2005 (2005-10-10), pages 324 - 331, XP027663478, ISSN: 0168-1656, [retrieved on 20051010] * |
ALEX CLOP ET AL: "A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep", NATURE GENETICS, vol. 38, no. 7, 4 June 2006 (2006-06-04), pages 813 - 818, XP055078053, ISSN: 1061-4036, DOI: 10.1038/ng1810 * |
ALEX CLOP: "Supplementary Figure 5", NATURE GENETICS, 4 June 2006 (2006-06-04), pages 1 - 3, XP055078055, Retrieved from the Internet <URL:http://www.nature.com/ng/journal/v38/n7/extref/ng1810-S5.pdf> [retrieved on 20130906] * |
DUMONCEAUX ET AL: "Improvement of Muscle Mass Using shRNA Targeting Myostatin or Activin Receptor IIb", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 13, 1 January 2006 (2006-01-01), pages S14, XP005675138, ISSN: 1525-0016 * |
PANTOPOULOS K ET AL: "The role of the 5' untranslated region of eukaryotic messenger RNAs in translation and its investigation using antisense technologies", PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, ACADEMIC PRESS, US, vol. 48, 1 January 1994 (1994-01-01), pages 181 - 238, XP009172334, ISSN: 0079-6603 * |
See also references of WO2008005002A1 * |
THOMAS R. MAGEE ET AL: "Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass", THE JOURNAL OF GENE MEDICINE, vol. 8, no. 9, 29 June 2006 (2006-06-29), pages 1171 - 1181, XP055078809, ISSN: 1099-498X, DOI: 10.1002/jgm.946 * |
ZADOR E ET AL: "Antisense inhibition of myoD expression in regenerating rat soleus muscle is followed by an increase in the mRNA levels of myoD, myf-5 and myogenin and by a retarded regeneration", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1590, no. 1-3, 12 June 2002 (2002-06-12), pages 52 - 63, XP004362110, ISSN: 0167-4889, DOI: 10.1016/S0167-4889(02)00198-2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008005002A1 (en) | 2008-01-10 |
CA2558160C (en) | 2017-01-03 |
AU2006345724B2 (en) | 2013-11-21 |
AU2006345724A1 (en) | 2008-01-10 |
CA2558160A1 (en) | 2007-12-30 |
EP2124968A1 (de) | 2009-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291175A (en) | Compositions and methods for treating collagen-mediated diseases | |
ZA200900388B (en) | Compositions and methods for the treatment of mucositis | |
HK1134679A1 (zh) | 用於治療感染的組合物和方法 | |
EP2361089A4 (de) | Behandlung einer veränderten synuclein-funktion | |
GB0700919D0 (en) | Degradable compositions, apparatus comprising same, and methods of use | |
IL193936A0 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
IL198723A0 (en) | Methods and compositions for therapeutic treatment | |
IL196843A0 (en) | Compositions and methods for the treatment of radiation proctosigmoitis | |
IL197804A0 (en) | Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c | |
EP2049151A4 (de) | Verfahren und zusammensetzungen zur behandlung von krebs | |
GB0718446D0 (en) | Compositions and methods for the treatment of infection | |
EP2124968A4 (de) | Zusammensetzungen und verfahren zur behandlung von muskelschwund | |
EP1996218A4 (de) | Verfahren und zusammensetzungen zur behandlung gastrointestinaler erkrankungen | |
EP2217238A4 (de) | Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit proteinurie | |
GB0909297D0 (en) | Composition for the treatment of skin conditions | |
IL187405A0 (en) | Methods and compositions for the treatment of pain | |
GB0718918D0 (en) | Compositions and methods for treating skin conditions | |
EP2096927A4 (de) | Therapeutische zusammensetzungen und behandlungsverfahren mit capsianosidartigen verbindungen | |
EP2285398A4 (de) | Verfahren und zusammensetzungen zur behandlung von adipositas | |
EP2142566A4 (de) | Verfahren und zusammensetzungen zur behandlung von proliferativen krankheiten | |
GB0620695D0 (en) | Composition and methods for the treatment of nurdegenerative disease | |
GB0504657D0 (en) | Compositions and methods of treatment | |
EP2094279A4 (de) | Verfahren und zusammensetzungen zur behandlung von influenza | |
ZA200710476B (en) | Methods and compositions for the treatment of pain | |
GB2441581B (en) | Compositions and methods for the treatment of muscle wasting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090513 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LAKEWOOD-AMEDEX, INC |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130920 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 21/04 20060101ALI20130916BHEP Ipc: A61K 31/70 20060101AFI20130916BHEP Ipc: C12N 5/00 20060101ALI20130916BHEP Ipc: C07H 21/02 20060101ALI20130916BHEP Ipc: C12Q 1/68 20060101ALI20130916BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140423 |